Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0FQ2U
|
||||
Former ID |
DIB005907
|
||||
Drug Name |
Talabostat
|
||||
Synonyms |
Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Hematopoietic [ICD10:D50-D89] | Phase 3 | [529167] | ||
Company |
Point Therapeutics; Tufts University School of Medicine
|
||||
Structure |
Download2D MOL |
||||
Formula |
C9H19BN2O3
|
||||
Canonical SMILES |
N1(C(=O)[C@@H](N)C(C)C)[C@H](B(O)O)CCC1
|
||||
CAS Number |
CAS 150080-09-4
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Seprase | Target Info | Inhibitor | [529167] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.